GYNECOLOGIC CANCERS

Camrelizumab and famitinib significantly enhance progression-free survival in recurrent cervical cancer compared to traditional chemotherapy, offering a promising new treatment option.

Early-stage cervical cancer treatment significantly boosts survival rates in older patients, highlighting the need for tailored care strategies.

Raludotatug deruxtecan (R-DXd) demonstrates significant antitumor activity and manageable safety in platinum-resistant ovarian cancer, paving the way for further studies.

TUB-040 shows over 50% response rates in platinum-resistant ovarian cancer, highlighting its potential as a promising treatment option.

New findings reveal pembrolizumab combined with paclitaxel enhances survival rates in patients with platinum-resistant recurrent ovarian cancer.

During a live event, Martin A. Martino, MD, analyzed overall survival outcomes from the PAOLA-1, SOLO-1, and PRIMA trials.

New clinical data reveals stenoparib significantly extends survival in advanced platinum-resistant ovarian cancer, offering hope for patients with limited options.

IMNN-001 shows promising results in enhancing the tumor microenvironment and improving survival rates in advanced ovarian cancer treatment.

New trial results reveal sacituzumab govitecan shows significant antitumor activity in recurrent cervical cancer, especially in heavily pretreated patients.

FDA designates raludotatug deruxtecan as a breakthrough therapy for treating platinum-resistant ovarian cancers, enhancing patient care options.

Rezatapopt shows promising efficacy in treating various tumors with TP53 Y220C mutations, highlighting its potential as a groundbreaking cancer therapy.

A new study reveals that pembrolizumab and bevacizumab offer a promising, less toxic treatment for recurrent ovarian cancer, especially the clear cell subtype.

FDA accepts relacorilant and nab-paclitaxel for platinum-resistant ovarian cancer, showing promising survival benefits in recent trials.

Researchers explore DNA methylation patterns for early ovarian cancer detection, aiming to improve survival rates through innovative blood tests.

FDA breakthrough therapy designation granted for rinatabart sesutecan in endometrial cancer, based on encouraging data from a phase 1/2 trial.

Incorporating molecular classification into preoperative staging for endometrial cancer improved risk stratification in patients with high-risk endometrial cancer.

Research reveals innovative methods for detecting minimal residual disease in ovarian cancer, enhancing prognosis and paving the way for targeted therapies.

Emerging treatments for low-grade serous ovarian cancer and platinum-resistant disease offer new hope, with promising data from recent clinical trials.

New research reveals that GLP-1 receptor agonists significantly lower mortality risk in older cancer patients with type 2 diabetes compared to other treatments.

Patient dosing has continued to successfully escalate in an early-phase trial of a novel FSHR-targeting CAR T-cell therapy in ovarian cancer.

Fertility preservation becomes crucial for reproductive-age cancer patients, emphasizing timely intervention and collaboration between oncology and reproductive specialists.

A significant number of patients with ovarian cancer miss preventive salpingectomy opportunities during unrelated surgeries.

A phase 3 trial showed that alpelisib plus olaparib did not reduce the risk of progression or death in relapsed/refractory ovarian cancer.

A promising allogeneic CAR T therapy has shown the potential to succeed in ovarian cancer where standard CAR-T treatments have failed.

The results support the potential for treatment de-escalation after hysterectomy for women with early-stage, intermediate-risk cervical cancer.